How We're Keeping You Safe | What Patients & Families Need to Know
< Back to Pediatric Cancer Research Studies Page
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed
To learn more about available clinical trials related to solid tumors, contact us at firstname.lastname@example.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2020 Cincinnati Children's Hospital Medical Center. All rights reserved.